MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-03-2025
Solid Biosciences Net Income 2011-2026 | SLDB
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Solid Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -125 M | -96 M | -86 M | -72.2 M | -88.3 M | -117 M | -74.8 M | -52.1 M | -21.5 M | -6.38 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -6.38 M | -125 M | -73.9 M |
Quarterly Net Income Solid Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -45.8 M | -39.5 M | -39.3 M | - | -32.7 M | -25.1 M | -24.3 M | - | -21 M | -24.6 M | -30.1 M | - | -20.4 M | -25.1 M | -25.3 M | - | -18 M | -18.7 M | -16.9 M | - | -21.2 M | -19 M | -26.7 M | -31.9 M | -29.3 M | -26.5 M | -29.6 M | -21.9 M | -19 M | -18 M | -15.9 M | -14.5 M | -53.2 M | -53.2 M | -53.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -14.5 M | -53.2 M | -28 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Drug manufacturers industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-20.1 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-26.5 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-74.8 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-598 M | $ 1.24 | 3.78 % | $ 133 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-13 M | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
-73.1 M | $ 2.67 | -0.19 % | $ 1.41 B | Canada |
 |
Agile Therapeutics
AGRX
|
-14.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
-1.04 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-27.6 M | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-510 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Eagle Pharmaceuticals
EGRX
|
35.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
HEXO Corp.
HEXO
|
-115 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Endo International plc
ENDP
|
-2.45 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-7.79 M | - | - | $ 36.6 M | USA |
 |
Emergent BioSolutions
EBS
|
-760 M | $ 13.83 | -0.61 % | $ 708 M | USA |
 |
Athenex
ATNX
|
-103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-48.8 M | $ 21.43 | -0.35 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
-50.4 M | $ 5.66 | - | $ 351 M | USA |
 |
Harrow Health
HROW
|
-24.4 M | $ 49.66 | -2.63 % | $ 1.62 B | USA |
 |
China Pharma Holdings
CPHI
|
-4.74 M | $ 1.35 | - | $ 23.6 M |  China |
 |
Jupiter Wellness
JUPW
|
-49.4 M | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
-131 M | $ 1.71 | 1.52 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
-592 M | $ 7.88 | -0.32 % | $ 2.88 B | Canada |
 |
Pacira BioSciences
PCRX
|
-99.6 M | $ 26.29 | 1.12 % | $ 1.22 B | USA |
 |
Lannett Company
LCI
|
-232 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.9 M | $ 4.9 | -5.59 % | $ 68.9 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
13.7 M | - | - | $ 193 M | Canada |
 |
Sundial Growers
SNDL
|
-230 M | $ 1.66 | 0.62 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.46 M | $ 3.83 | 2.41 % | $ 4.75 M | USA |
 |
Organogenesis Holdings
ORGO
|
861 K | $ 4.32 | 0.35 % | $ 569 M | USA |
 |
Aurora Cannabis
ACB
|
-695 M | $ 4.29 | 1.06 % | $ 86.3 M | Canada |
 |
PetIQ
PETQ
|
2.13 M | - | 1.64 % | $ 400 M | USA |
 |
Veru
VERU
|
-37.8 M | $ 2.38 | 0.21 % | $ 321 M | USA |
 |
Recro Pharma
REPH
|
-13.3 M | - | -4.76 % | $ 65.3 M | USA |
 |
Perrigo Company plc
PRGO
|
-172 M | $ 14.81 | 1.47 % | $ 2.03 B | USA |
 |
ProPhase Labs
PRPH
|
18.5 M | - | - | $ 5.07 M | USA |
 |
Rockwell Medical
RMTI
|
-8.44 M | $ 0.98 | 3.13 % | $ 22.9 M | USA |
 |
Radius Health
RDUS
|
-70.2 M | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
-153 K | $ 1.06 | -4.93 % | $ 4.57 M | USA |
 |
Relmada Therapeutics
RLMD
|
-98.8 M | $ 4.32 | - | $ 130 M | USA |
 |
OptiNose
OPTN
|
-35.5 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
-332 M | $ 9.38 | -0.53 % | $ 666 M | USA |
 |
PLx Pharma
PLXP
|
-46.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
67 M | $ 0.65 | 1.86 % | $ 31.1 M | USA |
 |
Tricida
TCDA
|
-177 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-1.45 B | $ 8.99 | - | $ 5.56 B | Canada |
 |
TherapeuticsMD
TXMD
|
-10.3 M | $ 2.0 | -1.96 % | $ 20.9 M | USA |
 |
Viatris
VTRS
|
2.08 B | $ 12.4 | -0.48 % | $ 15 B | USA |
 |
Zomedica Corp.
ZOM
|
-34.5 M | - | -0.21 % | $ 98 M | USA |